Pro Medicus: the quiet Melbourne software company that became an ASX darling

The short version is this: a Melbourne medical-imaging software company, founded by two doctors in the mid-1980s, spent roughly three decades building quietly before the Australian sharemarket decided it was extraordinary. By the early 2020s, Pro Medicus had a market capitalisation larger than many household Australian names — a figure that would have seemed fanciful to anyone watching the stock in, say, 2012, when it was still trading at a few dollars a share.

I've been watching Pro Medicus closely for the better part of two years now, and the more I look at it, the more it reads like the kind of story Australian business rarely tells well: not a miner, not a bank, not a property developer. Just software, and the patience to wait for the right customers.

Where it came from

Pro Medicus was founded in 1983 by Dr Sam Hupert and Dr Anthony Hall, both practising doctors with an interest in computing. The company started as a general medical software business — practice management tools, the unglamorous plumbing of a GP's office. For years it bumped along, doing useful work for the local market without attracting any particular excitement.

The pivot that mattered came with radiology. Hupert and Hall recognised that the real prize in medical computing was imaging: the vast, high-resolution files produced by MRI machines, CT scanners and digital X-ray systems. Radiologists needed software that could store, transmit and render these images reliably and quickly. The problem was technically hard. Most of the incumbent solutions were slow, expensive and deeply embedded in hospital IT infrastructure. Pro Medicus spent years developing its own imaging platform, Visage 7, which it acquired through the 2009 purchase of a German company called Visage Imaging. That acquisition — relatively modest in dollar terms at the time — turned out to be the defining move in the company's history.

What Visage 7 actually does (and why it matters)

Visage 7 is a viewer: the software a radiologist uses to look at medical images and write reports. But the technical architecture underneath it is what separates it from competitors. Most legacy systems in radiology — from vendors like Philips, Siemens Healthineers and GE HealthCare — work on a thick-client model, meaning heavy software installed on local machines, pulling enormous image files across hospital networks. Visage 7 was built from the ground up as a thin-client, streaming architecture. Only the pixels the radiologist is actually looking at in any given moment are transmitted, rather than the full file. In practice, this means images load faster, the system works over standard internet connections rather than dedicated hardware, and hospitals don't need to buy and maintain banks of local servers.

For large academic medical centres in the United States — which generate enormous volumes of imaging studies and often have multiple sites reading images remotely — that speed and scalability is not a minor convenience. It is genuinely mission-critical. And once a hospital has integrated its workflows, its PACS (picture archiving and communication systems) data, and its radiologists' habits into a single platform, switching costs are high. Not because Pro Medicus locks customers in contractually in some aggressive way, but because the cost and disruption of moving imaging infrastructure is real and significant.

That stickiness is the moat. And it shows up in the numbers.

The numbers I keep coming back to

Pro Medicus's financial profile is, honestly, unusual for an ASX-listed company of any kind. The business generates very high operating margins — consistently above 60 per cent at the EBIT level in recent years, according to the company's published annual reports. Revenue is predominantly recurring, built on long-term contracts with major US health systems. Customer churn is, by all available evidence, close to zero. The company carries no meaningful debt.

Revenue growth through the late 2010s and into the 2020s was sustained in the high-teens to low-twenties percentage range annually. That's the kind of compound growth rate that, over a decade, produces dramatic outcomes for shareholders who held on. The stock's performance over the decade to the mid-2020s placed it among the best-performing shares on the ASX, full stop — not just in the technology sector, but against everything.

I want to be careful here not to confuse a good business with a cheap stock. Pro Medicus has for several years traded at price-to-earnings multiples that would make a value investor's eyes water. Whether the current price is justified is a different question from whether the underlying business is excellent. My read is that the business is genuinely excellent; the valuation question is harder and I won't pretend otherwise.

The US market and the contract machine

The strategic story of the last decade is essentially Pro Medicus's systematic conquest of the large US academic medical centre market. The United States is, by far, the world's largest market for medical imaging software, and the big US health systems — the Mayo Clinics, the Johns Hopkins affiliates, the NYU Langones — represent the most prestigious and highest-volume customers available. Winning them is difficult; they run exhaustive procurement processes, involve large committees, and demand reference sites before committing.

Pro Medicus won its first significant US contract around 2012, with a Massachusetts hospital group. From there, each new name-brand contract became a reference for the next. The company has been consistently transparent in its ASX announcements about new contract wins, and the pattern over the 2010s and into the 2020s is striking: the contract values grew, the terms lengthened, and the counterparties became progressively more prestigious.

The sales motion is worth understanding. Pro Medicus does not run a large direct sales force in the way American enterprise software companies often do. The team is small. Revenue per employee at Pro Medicus is, by most measures, extraordinary — a function of the SaaS-style transaction model (customers pay per study read, not a flat licence fee) and the tight headcount discipline the company has maintained throughout. Hupert, who remains CEO, has spoken in various investor interviews about a deliberate choice to stay lean and not over-hire, particularly in sales and corporate functions. Whether that discipline holds as the company grows is something I'll be watching.

The competitive picture

The established competitors — Philips, Siemens, GE, Sectra, Intelerad — are not standing still. Philips in particular has invested heavily in its enterprise imaging portfolio. And the broader healthcare IT market is attracting significant venture and private-equity capital, which means newer entrants with modern architectures are also competing for some of the same customers.

Pro Medicus's advantage is not simply that Visage 7 is good today. It's that the company has a long track record of product investment, a reference network among the most demanding US academic centres, and a transaction-revenue model that aligns its interests with customer usage growth. Radiology volumes in the US, driven by an ageing population and expanding imaging modalities, are generally growing. That's a reasonable structural tailwind.

But I'd be cautious about anyone who presents this as a one-way bet. Enterprise software markets can shift — sometimes quickly, sometimes through technology disruption from an unexpected direction. Artificial intelligence in radiology is real and moving fast; whether it ultimately benefits Pro Medicus (by increasing the value of high-quality imaging infrastructure) or disrupts it (by changing the workflow around the viewer) is an open question. The company is investing in AI capabilities, but so is everyone else.

The people and the culture

Hupert and Hall still hold significant stakes in the company and both remain involved in the business. Hupert as CEO is, by the standards of ASX-listed technology companies, unusually present and candid in investor communications. He doesn't oversell. He talks about risks. He's explained the decision not to expand into adjacent markets not as a strategic triumph but as a deliberate choice to stay focused — and he acknowledges that focus means leaving some revenue on the table.

There's something in that restraint worth acknowledging. The history of Australian software companies that expanded too fast, lost discipline and ended up in trouble is not short. Pro Medicus has, at least so far, resisted that particular temptation. Whether that's wisdom or just luck compounded over time, I genuinely don't know. Probably both.

The company's Melbourne headquarters — for a while based in St Kilda Road before relocating — sits far from the noise of Silicon Valley and, for that matter, far from the ASX's habitual excitement about mining and property. It is, in some ways, the Australian outlier template: deep technical expertise, patient capital, a founder who didn't sell early and a market the locals mostly ignored until it was too late to get in cheap.

It belongs in the same conversation as Cochlear's long dominance of the hearing-implant market and the sustained global build of CSL — Australian companies that found a defensible niche in a global market and then held it, year after year, without much fanfare. That category is small. Pro Medicus has earned its place in it.

For anyone interested in how Australian companies actually win overseas — not through hype or Series D announcements but through compounding technical credibility — this is the story to study. More on that kind of company in our Outliers & Global Empires section.